Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 77.50% is 31% above its 5-year average of 59.00%, near the high end of its 5-year range (-16.58%–79.85%).
0.65% above its 12-month average of 77.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.72%.
GROSS MARGIN
77.50%
GROSS MARGIN AVG TTM
77.00%
GROSS MARGIN AVG 3Y
68.52%
GROSS MARGIN AVG 5Y
59.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.65%
CURRENT VS 3Y AVG
+13.10%
CURRENT VS 5Y AVG
+31.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+87.29%
vs the sector median at left
Market Cap
$192.56M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$189.11M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$184.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$183.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$181.30M
Gross Margin
0.65%
TTM Avg
0.33%
3Y Avg
50.16%
5Y Avg
60.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | $192.06M | 77.50% | 77.00% | 68.52% | 59.00% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.56M | 0.00% | 50.00% | 25.00% | 16.67% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alector, Inc. (ALEC)vs › | $200.97M | 54.09% | -15.41% | 40.02% | -79.15% |
| Surrozen, Inc. (SRZN)vs › | $201.59M | 84.56% | 92.28% | 64.60% | 43.07% |
| Exagen Inc. (XGN)vs › | $202.17M | 58.64% | 58.89% | 55.18% | 56.44% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.30M | 0.65% | 0.33% | 50.16% | 60.13% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.96M | 0.00% | 50.00% | 25.00% | 16.67% |
Gross Margin
77.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 76.72% |
| 2026-03-31 | 76.06% |
| 2025-12-31 | 77.48% |
| 2025-09-30 | 79.85% |
| 2025-06-30 | 74.89% |
| 2025-03-31 | 74.76% |
| 2024-12-31 | 71.59% |
| 2024-09-30 | 55.54% |
| 2024-06-30 | 69.51% |
| 2024-03-31 | 70.09% |
| 2023-12-31 | 61.77% |
| 2023-09-30 | 44.77% |
| 2023-06-30 | 57.74% |
| 2023-03-31 | 59.27% |
| 2022-12-31 | 46.13% |
| 2022-09-30 | 42.46% |
| 2022-06-30 | 42.15% |
| 2022-03-31 | 42.06% |
| 2021-12-31 | 34.05% |
| 2021-09-30 | 23.18% |
| 2021-06-30 | -16.58% |
| 2021-03-31 | 32.12% |
| 2020-12-31 | 28.08% |
| 2020-09-30 | 17.27% |
| 2020-06-30 | -17.52% |
| 2020-03-31 | 2.70% |
